‘A really rational IPO environment’: What does it takes for a biotech to go public now?

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal.

“This is a really rational IPO environment,” Sofinnova Investments General Partner Maha Katabi, Ph.D., said during Fierce’s J.P. Morgan Week panel on Jan. 15. “I hear a lot of lament about not enough IPOs. But you know what? It's really great to be in an environment where the right companies are the ones that are accessing the public markets.”